WASHINGTON (Reuters) - An advisory panel to the U.S. Food and Drug Administration recommended on Wednesday that AstraZeneca Plc be required to submit further clinical data before its experimental ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results